These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 29247558)

  • 1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016].
    Nádasdi Á; Somogyi A; Igaz P; Firneisz G
    Orv Hetil; 2018 Nov; 159(45):1815-1830. PubMed ID: 30415572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.
    Ciardullo S; Sala I; Perseghin G
    Diabetes Res Clin Pract; 2020 Sep; 167():108358. PubMed ID: 32745698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD.
    Ciardullo S; Ronchetti C; Muraca E; Oltolini A; Perra S; Bianconi E; Zerbini F; Cannistraci R; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    J Endocrinol Invest; 2020 Jul; 43(7):1019-1026. PubMed ID: 32008185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
    Perazzo H; Munteanu M; Ngo Y; Lebray P; Seurat N; Rutka F; Couteau M; Jacqueminet S; Giral P; Monneret D; Imbert-Bismut F; Ratziu V; Hartemann-Huertier A; Housset C; Poynard T;
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1081-93. PubMed ID: 25186086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preperitoneal fat as a non-invasive marker of increased risk of severe non-alcoholic fatty liver disease in patients with type 2 diabetes.
    Parente DB; Oliveira Neto JA; Brasil PEAA; Paiva FF; Ravani JPR; Gomes MB; Lanzoni V; Campos CFF; Machado-Silva L; Perez RM; Rodrigues RS
    J Gastroenterol Hepatol; 2018 Feb; 33(2):511-517. PubMed ID: 28726335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    ; ;
    J Hepatol; 2016 Jun; 64(6):1388-402. PubMed ID: 27062661
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
    Tai FW; Syn WK; Alazawi W
    Diabet Med; 2015 Sep; 32(9):1121-33. PubMed ID: 25683343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
    Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
    Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study.
    Besutti G; Bonilauri L; Manicardi E; Venturelli F; Bonelli E; Monelli F; Manicardi V; Valenti L; Ligabue G; Schianchi S; Massari M; Riva N; Froio E; Tagliavini E; Pattacini P; Giorgi Rossi P
    Diabetes Res Clin Pract; 2021 Jul; 177():108882. PubMed ID: 34082056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
    Poynard T; Lassailly G; Diaz E; Clement K; Caïazzo R; Tordjman J; Munteanu M; Perazzo H; Demol B; Callafe R; Pattou F; Charlotte F; Bedossa P; Mathurin P; Ratziu V;
    PLoS One; 2012; 7(3):e30325. PubMed ID: 22431959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interpretation of the 2024 American Diabetes Association guidelines for the comprehensive management of non-alcoholic fatty liver disease combined with diabetes mellitus].
    Ni WJ; Li J; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2024 Jun; 32(6):504-507. PubMed ID: 38964892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
    J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
    Petroff D; Blüher M; Wiegand J
    Dig Liver Dis; 2018 Jul; 50(7):731-733. PubMed ID: 29699861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.